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TP is well known for its role as an intracellular energy
source. However, there is increasing awareness of
its role as an extracellular messenger molecule
(Burnstock, 1997). Although evidence for the presence of
receptors for extracellular ATP on skeletal myoblasts was
ﬁrst published in 1983 (Kolb and Wakelam), their physio-
logical function has remained unclear. In this paper we
used primary cultures of rat skeletal muscle satellite cells
to investigate the role of purinergic signaling in muscle
formation. Using immunocytochemistry, RT-PCR, and electro-
physiology, we demonstrate that the ionotropic P2X
 
5
 
 receptor
is present on satellite cells and that activation of a P2X
A
 
receptor  inhibits proliferation, stimulates expression of
markers of muscle cell differentiation, including myogenin,
p21, and myosin heavy chain, and increases the rate of
myotube formation. Furthermore, we demonstrate that
ATP application results in a signiﬁcant and rapid increase
in the phosphorylation of MAPKs, particularly p38, and
that inhibition of p38 activity can prevent the effect of
ATP on cell number. These results not only demonstrate
the existence of a novel regulator of skeletal muscle differ-
entiation, namely ATP, but also a new role for ionotropic
P2X receptors in the control of cell fate.
 
Introduction
 
The first report of the transmitter-like action of ATP on the cell
membranes of myoblasts and myotubes (Kolb and Wakelam,
1983) was published prior to the discovery and cloning of the
P2X receptor family (for review see Ralevic and Burnstock,
1998). It is now well established that ATP can exert its effects
via activation of either P2X or P2Y receptors (for review see
Ralevic and Burnstock, 1998). P2X receptors are ligand-gated
ion channels and activation of these receptors by extracellular
ATP elicits a flow of cations (Na
 
 
 
, K
 
 
 
, and Ca
 
2
 
 
 
) across the
plasma membrane. To date, seven mammalian P2X receptor
subunits (P2X
 
1–7
 
) capable of assembling into homo- or hetero-
multimeric receptors have been cloned (Torres et al., 1999).
In contrast, P2Y receptors are G protein–coupled receptors,
which act principally by activating phospholipase C, leading to
formation of inositol 1,4,5-trisphophate and the mobilization
of intracellular Ca
 
2
 
 
 
 (Ralevic and Burnstock, 1998). Although,
a role for P2Y receptors in mediating the trophic effects of ATP
is widely recognized (Neary et al., 1996; Abbracchio and
Burnstock, 1998), P2X receptors are still largely viewed
as mediators of short-term, fast cell–cell communication.
However, recent studies demonstrating P2X
 
7
 
-dependent apop-
tosis (Coutinho-Silva et al., 1999; Humphreys et al., 2000)
and P2X
 
5
 
 expression in the differentiating cell layers of stratified
squamous epithelial tissues (Gröschel-Stewart et al., 1999),
suggest that P2X receptors could also mediate trophic effects,
including cell proliferation, differentiation, and apoptosis.
These processes are of key importance in skeletal muscle
regeneration. Because skeletal myofibers are terminally
differentiated, the regeneration of skeletal muscle is largely
dependent on a small population of resident, quiescent
cells, termed satellite cells (Perry and Rudnicki, 2000; Seale
and Rudnicki, 2000). In response to muscle damage, satellite
cells proliferate, become committed to differentiation, exit
the cell cycle, and fuse to form multinucleated myotubes.
As in muscle development, the MyoD family of basic-helix-
loop-helix transcription factors (known as myogenic regulatory
factors) is required for the commitment and differentiation
of satellite cells during regeneration. This process is also
closely tied to cell cycle activity (Lassar et al., 1994; Walsh and
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Perlman, 1997; Perry and Rudnicki, 2000). Proliferating skele-
tal satellite cells express high levels of MyoD and Myf5, but on
commitment to terminal differentiation these transcription fac-
tors are downregulated, and myogenin expression increases.
This is followed by activation of the cell cycle arrest protein,
p21, and permanent exit from the cell cycle. The differentiation
program is then completed with the activation of muscle spe-
cific proteins, such as myosin heavy chain (MHC)* and fusion
to form multinuclear myotubes (Walsh and Perlman, 1997;
Perry and Rudnicki, 2000; Seale and Rudnicki, 2000).
It has long been recognized that the processes of skeletal satel-
lite cell proliferation and differentiation are mutually exclusive
(Lassar et al., 1994; Walsh and Perlman, 1997). Understanding
the signaling systems involved in directing these cells between
proliferation and differentiation is of key importance in devel-
oping new therapeutic strategies to treat muscle injury and dis-
ease. Many factors, including fibroblast growth factors, insulin-
like growth factors, and interleukin-6 cytokines, have already
been implicated in the control of satellite cell activity (Hawke
and Garry, 2001). In the case of insulin-like growth factors and
fibroblast growth factors, the MAPKs have been shown to be
involved in mediating these effects (Campbell et al., 1995;
Weyman and Wolfman, 1998; Conejo and Lorenzo, 2001; Adi
et al., 2002). In particular, extracellular signal-regulated protein
kinases (ERKs) 1/2 and p38 MAPK activity has been shown to
be involved in directing myogenesis. Whereas a number of
studies have demonstrated the importance of the ERK 1/2
pathway in myoblast proliferation (Bennett and Tonks, 1997;
Jones et al., 2001), activation of p38 isoforms has been shown
to stimulate commitment to differentiation and myotube for-
mation (Chun et al., 2000; Wu et al., 2000; Zetser et al., 1999).
Recent publications demonstrating the expression of ATP
receptor subunits (P2X
 
2
 
, P2X
 
5
 
, and P2X
 
6
 
) during skeletal
muscle development (Meyer et al., 1999b; Ruppelt et al.,
2001; Ryten et al., 2001) suggest that ATP might also act as a
trophic factor in skeletal muscle formation. In this paper we
used primary cultures of neonatal, rat, skeletal muscle satellite
cells to study the role of purinergic signaling in muscle regen-
eration. We present evidence for the regulated expression of
the ionotropic P2X
 
5
 
 receptor protein and mRNA on satellite
cells and demonstrate that activation of a P2X receptor inhib-
its proliferation of satellite cells. Because the processes of
myoblast proliferation and differentiation are mutually exclu-
sive (Lassar et al., 1994; Walsh and Perlman, 1997
 
)
 
, we also
tested the ability of ATP to potentiate differentiation and in-
vestigated some of the intracellular mechanisms that might
be responsible for mediating these effects.
 
Results
 
ATP can inhibit satellite cell proliferation under 
differentiating (low serum) conditions
 
It is well recognized that satellite cell differentiation, is po-
tentiated by transferring cells from high serum (growth me-
dia [GM]) to low serum (differentiation media [DM])
(Daniels et al., 2000). The effect of ATP on cell prolifera-
tion was determined for cells plated at low density (to pre-
vent myotube formation) and maintained under both condi-
tions (GM and DM). Although cells proliferated more
slowly in DM as compared with GM, under both conditions
the cell number increased significantly after 24 h (DM,
140% 
 
 
 
 10.0%; GM, 404% 
 
 
 
 10.5% of cell number on
plating). At a concentration of 10–100 
 
 
 
M, ATP signifi-
cantly inhibited (P 
 
 
 
 5%) the expected increase in the num-
ber of satellite cells. At 24 h, ATP reduced the total number
of cells present to 67.1% 
 
 
 
 4.3% of that seen in untreated
cultures (Fig. 1 A, red). However, ATP had no significant
effect on cells maintained in GM (Fig. 1 A, black). ATP
acted in a concentration-dependent manner and completely
inhibited the expected increase in cell number (even after
72 h) when applied at a maximal concentration of 500 
 
 
 
M
(Fig. 1 B). However, at no point did addition of ATP, at any
concentration, result in a fall in cell number below that at
plating (i.e., Fig. 1 B, 100%). This suggests that ATP did
not cause cell death, but inhibited cell proliferation. This in-
terpretation was confirmed using BrdU incorporation stud-
ies. Addition of 100 
 
 
 
M ATP resulted in a 35% 
 
  
 
4.5% re-
duction (as compared with control) in the percentage of cells
staining for BrdU, indicating that cells exposed to ATP had
a reduced proliferation rate (Fig. 1 C, a and b).
 
The effect of ATP on satellite cell proliferation
at 24 h cannot be replicated by ADP, UTP,
or adenosine and is inhibited by pyridoxal
5-phosphate-6-azophenyl-2
 
 
 
,4
 
 
 
-disulfonic acid
 
In order to determine which receptors were involved in
mediating the effect of ATP on satellite cell proliferation,
we applied a variety of agonists and antagonists, each spe-
cific to a different range of purinoceptors. ATP, ADP,
UTP, and 
 
 
 
-
 
 
 
-methylene ATP were applied to cells
(maintained in DM) at 1–100-
 
 
 
M concentrations. ATP
significantly inhibited cell proliferation, whereas the P2Y
receptor agonists, ADP, an agonist at P2Y
 
1
 
 and P2Y
 
12
 
 re-
ceptors (Ralevic and Burnstock, 1998), and UTP an ago-
nist at P2Y
 
2
 
, P2Y
 
4
 
, and P2Y
 
6
 
 receptors (Ralevic and Burn-
stock, 1998), did not inhibit cell proliferation (Fig. 2 A).
In fact, UTP significantly increased the cell number (Fig. 2
A). The P2X
 
1
 
 and P2X
 
3
 
 selective agonist, 
 
 
 
-
 
 
 
-methylene
ATP, had no effect on cell number.
ATP can be hydrolyzed to adenosine and this is also an
important signaling molecule. Consequently, we tested
the effect of adenosine at 1–100-
 
 
 
M concentrations on
satellite cell number (Fig. 2 A). Unlike ATP, adenosine
application did not reduce cell number at 24 h. However,
when adenosine was applied for 72 h at a concentration of
100 
 
 
 
M, a greater concentration than required to demon-
strate an ATP effect, a reduction in proliferation was ob-
served (Fig. 2 C). This adenosine effect (100 
 
 
 
M) was in-
hibited by 8-(p-sulfophenyl)-theophylline (8-SPT) (30
 
 
 
M), but not dipyridamole, suggesting that this effect was
due to activation of a P1 receptor and not secondary to
the uptake of adenosine (Fig. 2 C).
The antiproliferative activity of ATP measured at 24 h
could not be inhibited by the P2 receptor antagonist reactive
 
*Abbreviations used in this paper: 8-SPT, 8-(p-sulfophenyl)-theophylline;
DM, differentiation media; ERK, extracellular signal-regulated protein
kinase; GM, growth media; JNK, c-Jun NH
 
2
 
-terminal kinase; MHC,
myosin heavy chain; NGS, normal goat serum; NHS, normal horse
serum; PPADS, pyridoxal 5-phosphate-6-azophenyl-2
 
 
 
,4
 
 
 
-disulfonic
acid; RB2, reactive blue 2. 
 
 
ATP regulates skeletal muscle differentiation |
 
 Ryten et al. 347
 
blue 2 (RB2) (preapplied for 20 min at 50 
 
 
 
M), but was
fully inhibited by pyridoxal 5-phosphate-6-azophenyl-2
 
 
 
,4
 
 
 
-
disulfonic acid (PPADS) (preapplied for 20 min at 10 
 
 
 
M)
(Fig. 2 B). At 72 h, the effect of ATP was only partially in-
hibited by this antagonist.
 
Satellite cells express P2X receptors and the expression 
of P2X
 
5
 
 receptor protein and mRNA is regulated by 
serum conditions
 
We investigated the presence of different P2X receptor
subunits on satellite cells maintained in growth and differ-
entiating media by using selective antibodies to P2X
 
1–7
 
.
We were unable to detect significant immunoreactivity for
any of these receptors in cells maintained in GM. In con-
trast, cells maintained in DM were strongly immunoposi-
tive for the P2X
 
5
 
 receptor subunit only (Fig. 3 A). Using
Figure 1. ATP inhibits satellite cell proliferation. (A) ATP 
significantly reduced (P   5%) the number of satellite cells when 
maintained in DM (red) for 24 h (by 32.9%   4.3%, when ATP was 
applied at 100  M), but had no significant effect on cells maintained 
in GM (black). (B) ATP was applied to cells maintained in DM and 
cell number assessed 24, 48, and 72 h after application. At all three 
time points, ATP at concentrations of 50–500  M reduced the number 
of cells. However at no point did ATP cause a reduction in cell number 
below that at plating (i.e., 100%). Values significantly different from 
respective controls are denoted by * (P   5%). (C) BrdU incorporation 
assay. (a) BrdU immunostaining (green) demonstrated cell proliferation 
in control cultures (24 h). (b) Application of 100  M ATP for 24 h 
significantly (P   5%) reduced the proportion of BrdU-positive cells. 
(c and d) Similar numbers of cells were present in control and 
ATP-treated cultures (DAPI staining, blue). Bars, 100  m.
Figure 2. ATP inhibits satellite cell proliferation by activation of a 
P2X receptor. (A) The inhibitory effect of ATP on cell number at 
24 h was not replicated by adenosine, ADP, UTP, or  ,  -methylene 
ATP. In fact, UTP significantly increased cell number. Values 
significantly different from control (P   5%) are denoted by *. 
(B) Preapplication of PPADS (10  M) for 20 min, but not RB2 (50  M) 
completely inhibited the effect of ATP at 24 h. PPADS produced a 
partial inhibition at 72 h, probably due to the break down of ATP to 
adenosine and subsequent activation of a P1 receptor. Values 
significantly different from ATP application alone on respective 
days (P   5%) are denoted by *. (C) Application of 100  M 
adenosine (Ad) resulted in a significant (P   5%) reduction in cell 
number at 72 h. This could be inhibited by preapplication of the P1 
receptor antagonist, 8SPT (30  M). Values significantly different 
from control (P   5%) are denoted by *. 
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semiquantitative RT-PCR, we were able to demonstrate
increased expression of P2X
 
5
 
 receptor mRNA (Fig. 3 B).
RT-PCR experiments also provided evidence for the ex-
pression of P2X
 
2
 
, P2X
 
4
 
, and P2X
 
6
 
 receptor mRNA (Fig. 3
B). P2X
 
2
 
 receptor mRNA was expressed only at a very low
level in cells maintained in DM, whereas P2X
 
4
 
 and P2X
 
6
 
receptor mRNA was expressed at similar levels in cells
maintained under both conditions. Because the only P2X
receptors to be differentially expressed were P2X
 
2
 
 and
P2X
 
5
 
, this would implicate these receptors in the differen-
tial response to ATP of cells maintained in growth or dif-
ferentiation medium and consequently the antiproliferative
effects of ATP.
 
ATP activates a cation conductance in satellite cells
 
We further investigated the action of ATP on skeletal mus-
cle satellite cells using electrophysiology. Cells were plated
at low density and voltage clamped using the whole cell
patch clamp technique. Rapid application of 10 
 
 
 
M ATP
to voltage clamped cells evoked a small, sustained inward
current of 9.7 
 
 
 
 1.6 pA (
 
n
 
 
 
 
 
 22). These responses re-
flected a current density of 0.87 
 
 
 
 0.1 pA/pF and acti-
vated and inactivated quickly (Fig. 4 A). In contrast, UTP
and ADP, which are potent agonists at some subtypes of
P2Y receptors (at a concentration of 100 
 
 
 
M), failed to
evoke any significant response. The response to ATP was
associated with an increase in membrane conductance. The
current voltage relationship showed pronounced inward
rectification and a reversal potential close to 0 mV (Fig. 4
B; mean reversal potential 
 
 
 
3.8 
 
 
 
 4.7 mV, 
 
n
 
 
 
 
 
 8) indica-
tive of a nonselective cation conductance. The purinocep-
tor antagonist PPADS produced a potent inhibition of the
response to ATP (Fig. 4 C), which reversed only very
slowly on washout.
 
ATP application increased the expression of markers of 
terminal differentiation and these effects could be 
inhibited by preapplication of the purinoceptor 
antagonist PPADS
 
Because the processes of skeletal satellite cell proliferation
and differentiation are mutually exclusive (Lassar et al.,
1994; Walsh and Perlman, 1997), ATP might be expected
not only to inhibit satellite cell proliferation, but potenti-
ate differentiation. Addition of 100 
 
 
 
M ATP increased the
expression of myogenin and p21, as judged by semiquanti-
tative RT-PCR (Fig. 5 A). Preapplication of 10 
 
 
 
M
PPADS for 20 min inhibited this effect (Fig. 5 A). In-
creased expression of p21 by skeletal muscle satellite cells
would be expected to result in irreversible cell cycle exit,
such that removal of ATP would not rescue cells. In fact
we found that treatment of satellite cell cultures with 100
 
 
 
M ATP for only 1 min (Fig. 5 B), was sufficient to cause
Figure 3. Regulation of P2X receptor protein and mRNA in satellite 
cells in vitro. (A) Immunocytochemistry for P2X5 (green) and DAPI 
(blue) demonstrated that cells maintained in DM for 24 h stained 
more strongly for P2X5 than those maintained in GM. Note that 
photographs were taken using identical exposure times. Bar, 50  m. 
(B) Semiquantitative RT-PCR was used to investigate the expression 
of P2X receptor mRNA in satellite cells. Cells maintained in DM, 
expressed higher levels of P2X5 receptor mRNA compared with 
cells maintained in GM. Similarly P2X2 receptor mRNA was only 
expressed on cells in DM. P2X4 and P2X6 receptor mRNA was also 
expressed by skeletal satellite cells, but expression was not effected 
by changes in medium.
Figure 4. Nucleotide responses of myoblasts recorded under 
whole-cell voltage clamp at –60 mV. (A) Whereas 10  M ATP 
evokes a rapidly activating, sustained inward current, a tenfold 
higher concentration of the P2Y receptor agonists UTP and ADP 
failed to evoke a response. (B) The current-voltage relationship for 
the ATP activated current reveals inward rectification and a reversal 
potential close to 0 mV. (C) The response to 10  M ATP is inhibited 
by the purinoceptor antagonist PPADS, and recovers slowly on 
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a significant reduction in cell number at 72 h (28.8%  
3.2%, P   5%). Preapplication of PPADS (red), but not
8-SPT, inhibited this effect (Fig. 5 B), confirming that the
effects of ATP are due primarily to P2 and not P1 receptor
activity. Furthermore, ATP application significantly in-
creased (P   5%) the number of cells expressing MHC
(194.3%   14.6% when 100  M ATP applied for 24 h)
(Fig. 5 C) and the number of myotubes formed in 24 h
(Fig. 5, D and E) (201%   12.1% when 50  M ATP ap-
plied). The increased MHC expression produced by ATP
(100  M) could be inhibited by preapplication of PPADS
(10  M), but not RB2 (50  M).
ATP application increased the phosphorylation of 
p38 and ERK 1/2
MAPK signalling cascades have been implicated in the regu-
lation of myogenesis. Whereas the ERKs have been impli-
cated in myoblast proliferation (Bennett and Tonks, 1997;
Jones et al., 2001), the p38 pathway has been implicated in
myoblast differentiation (Chun et al., 2000; Wu et al., 2000;
Zetser et al., 1999). We used antibodies specific for the
active (phosphorylated) and inactive (nonphosphorylated)
forms of the p38 and ERK 1/2 proteins, to assess these sig-
naling pathways at a range of time points (Fig. 6, A and B).
Consistent with previous studies (Wu et al., 2000; Zet-
ser et al., 1999), we found that maintaining cells in DM in
itself (without the addition of ATP) had significant effects
on the p38 MAPK pathway. Even in untreated cultures,
the levels of phosphorylated p38 significantly (P   5%) in-
creased when cultures were maintained in DM for  24 h
(7.2   1.9-fold increase in p38 phosphorylation at 24 h
relative to time zero). However, as reported by Wu et al.
(2000), we found no significant difference in ERK 1/2
phosphorylation relative to time zero when cells were
maintained in DM for 24 h (2.0   0.8-fold increase in
ERK 1 phosphorylation at 24 h).
Figure 5. Treatment of satellite cells with ATP increases the 
expression of markers of differentiation. (A) Semi-quantitative 
RT-PCR demonstrated increased expression of myogenin and p21 
mRNA in cells treated with 100  M ATP for 24 h. Pre-application of 
PPADS inhibited the increase of both myogenin and p21. The 
ribosomal protein, 16S was used as an internal control. (B) Application 
of 100  M ATP for 1 min, followed by replacement with fresh 
media without ATP, was sufficient to cause a significant (P   5%) 
reduction in cell number (of 28.8%   3.2% compared with 
untreated controls) at 72 h. This effect could be fully inhibited by 
PPADS (10  M), but not 8-SPT (30  M). (C) ATP application for 24 h 
caused a concentration-dependent increase in the number of cells 
positive for MHC. The effect of ATP (100  M) could be inhibited by 
preapplication of PPADS (10  M for 20 min), but not RB2 (50  M). 
Values significantly different from control (P   5%) are denoted by *. 
(D) Treatment of confluent cultures with 0.05–50  M ATP for 24 h 
resulted in a concentration-dependent increase in myotube formation. 
Above a concentration of 50  M, the strong anti-proliferative effect of 
ATP and consequent reduction in cell density, reduced the number 
of myotubes formed. Values significantly different from control 
(P   5%) are denoted by *. (E) Treatment of confluent cultures with 
50  M ATP for 24 h resulted in significantly increased (P   5%) 
numbers of myotubes (201%   12.1%) (arrowheads). Myotubes are 
visible in cultures stained with DAPI for nuclei (blue) and skeletal 
myosin (red), as multinuclear cells, strongly immunopositive for 
myosin. Bars, 200  m.350 The Journal of Cell Biology | Volume 158, Number 2, 2002
Despite the basal activities of the MAPK pathways, we
found that treatment with ATP caused a rapid and signifi-
cant increase in the levels of phosphorylated p38 and ERK
1/2. Application of 100  M ATP to cultures maintained
in DM caused a significant increase (P   5%) in p38 phos-
phorylation at 5 and 10 min (6.9   0.9- and 11.0   1.4-
fold increase in p38 phosphorylation at 5 and 10 min, re-
spectively, relative to time zero) (Fig. 6, A and B). Similar
but less dramatic changes were also seen with ERK 1/2
phosphorylation. The fold increases in ERK 1/2 were 4.5  
1.0 and 6.5   1.8, respectively at 10 min (Fig. 6, A and
Figure 6. ATP application to satellite cells maintained in DM 
causes a rapid and transient increase in phosphorylation of p38 
and ERK1/2. (A) Western blotting demonstrated that application of 
100  M ATP to cultures increased the levels of phosphorylated 
p38 and ERK 1/ 2. Relative to time zero, ATP caused a significant 
(P   5%) increase in the levels of ERK 1/ 2 phosphorylation at 1, 5, 
and 10 min, but not 30 min. Similarly, ATP caused a significant 
increase in the levels of phosphorylated p38 at 5 and 10 min, but 
not 30 min. In both the cases, the peak of phosphorylation was at 
10 min and the effect of ATP was transient. Consequently there was 
no significant difference in the levels of phosphorylated p38 and 
ERK 1/2 in treated and control cultures 1 h after ATP application. 
It should also be noted that in untreated cultures, the levels of 
phosphorylated p38 had significantly increased at 1 h and 24 h, but 
there was no significant change in the level of ERK1/2 phosphorylation 
over the same time period. ATP did not have any effect on the levels 
of total p38 or ERK 1/2. Representative Western blots are shown 
from one set of treated cells. (B) The levels of phosphorylated p38, 
ERK 1 and ERK 2 from three independent experiments were analyzed 
using densitometry and plotted as fold increases in phosphorylated 
protein, compared with the levels at time 0. Phosphorylated p38 is 
plotted in red, ERK 1 in blue and ERK 2 in green.
Figure 7. Inhibitors of the MAPK pathways have effects on satellite 
cell number, but only the inhibitor of p38  and p38  activation 
(SB203580) blocked the effects of ATP. (A) PD98059 (50  M), U0126 
(10  M) and SB203580 (10  M) were applied to satellite cells, 
maintained in GM or DM for 12–16 h, the medium changed and cell 
number assessed at 24 h. Inhibitors of ERK 1/2 activation (PD 98059 
and U0126) caused a significant reduction (P   5%) in cell number, 
when cells were maintained in GM or DM. This effect was greater on 
cells maintained in GM, than those in DM. Application of U0126 
caused a 34.84%   4.01% decrease in cell number at 24 h, when cells 
were maintained in GM, as compared with an 11.73%   1.64% 
decrease, when cells were maintained in DM. SB203580 application 
had no significant effect on cell number when cells were maintained in 
GM or DM. Values significantly different from the relevant control (DM 
or GM) (P   5%) are denoted by *. (B) Inhibitors of the ERK 1/2, p38, 
and JNK MAPK signaling pathways (PD98059, U0126, SB203580 and 
dicumarol) were tested for their ability to inhibit the effect of ATP on 
satellite cell number. PD98059 (50  M), U0126 (10  M), dicumarol 
(100  M), and SB203580 (10  M) were preapplied for 30 min in the 
case of PD98059 and U0126, and 1 h in the case of dicumarol and 
SB203580, before application of ATP. As previously demonstrated 
application of 10 or 100  M ATP caused a significant reduction in cell 
number. These effects were not inhibited by PD98059, U0126, or 
dicumarol. However, SB203580 an inhibitor of p38  and p38 
activation completely prevented the effect of 10  M ATP and partially 
prevented the effect of 100  M ATP. Values significantly different from 
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B). These effects were transient, such that 1 h after applica-
tion, there was no significant difference in p38 or ERK 1/2
phosphorylation between treated and untreated cultures
(Fig. 6 A). After 3 h, cultures treated with ATP had levels
of p38 phosphorylation, which were not significantly dif-
ferent from the levels of p38 phosphorylation in untreated
cultures after 1 or 24 h (Fig. 6 A).
Inhibition of p38 activity prevented the ATP-dependent 
reduction in cell proliferation
In order to determine whether the trophic effects of ATP
were dependent on activation of MAPK signaling pathways,
we used a variety of specific inhibitors of MAPK activity.
We found that application of specific inhibitors of MEK1
(responsible for ERK activation), PD95809, and U0126
(Alessi et al., 1995; Favata et al., 1998), resulted in a de-
crease in cell number (Fig. 7 A). This effect was greater on
cells maintained in GM than on cells maintained in DM. At
24 h, U0126 (10  M) reduced the total number of cells
present to 65.16%   4.01% of that seen on treated cultures,
when cells were maintained in GM, as compared with
88.27%   1.64%, when cells were maintained in DM (Fig.
7 A). In contrast, SB203580, the specific inhibitor of p38 
and p38  MAPKs (Lee et al., 1994; Cuenda et al., 1995),
had no significant effect on cell number when cells were
maintained in either GM or DM (Fig. 7 A).
These inhibitors were also tested for their ability to pre-
vent the effects of ATP on satellite cells (Fig. 7 B). As previ-
ously demonstrated, ATP caused a significant reduction in
cell number at 24 h when applied at concentrations of 10–
100   M. The effect of 10  M ATP on cell number
(61.90%   3.15% of that seen on untreated cultures) was
completely inhibited by preapplication of SB203580 (Fig. 7
B), but not by preapplication of PD98059 (50  M), U0126
(10  M), or dicumarol (a specific inhibitor of c-Jun NH2-
terminal kinase (JNK) activity, when applied at a concentra-
tion of 100  M) (Cross et al., 1999; Krause et al., 2001)
(Fig. 7 B). Similarly, only SB203580 inhibited the effects of
100  M ATP at 24 h. In this case, the effects of ATP on cell
number were partially inhibited (Fig. 7 B).
Discussion
Although Kolb and Wakelam’s (1983) demonstration of
the transmitter-like effects of ATP on chick skeletal muscle
cultures prompted a number of studies on the effects of
ATP and other nucleotides on myotubes, there has been lit-
tle further research on myoblasts. In this paper, we use pri-
mary cultures of rat skeletal muscle satellite cells to identify
not only the P2 receptor subtypes expressed by myoblasts,
but to demonstrate that activation of these receptors can
regulate muscle formation. ATP acts on cells maintained in
low-serum conditions to inhibit proliferation and potenti-
ate the expression of markers of differentiation including
myogenin and p21. Surprisingly, we found that these ef-
fects were mediated by an ionotropic P2X receptor, con-
taining the P2X5 receptor subunit and involved activation
of the MAPK signaling cascades.
Primary rat satellite cells in vitro proliferate, commit to
differentiation and fuse to form myotubes in a manner anal-
ogous to muscle formation in vivo. This has allowed us to
investigate the effects of ATP on skeletal muscle regenera-
tion in an easily accessible and well-characterized system.
Using this model, we found that ATP had significant effects
on satellite cell activity. Application of 100  M ATP in-
creased the expression of myogenin and the cell cycle arrest
protein p21 at 24 h, and these effects could be blocked using
PPADS. Expression of these nuclear proteins has been
shown to be necessary for terminal differentiation of myo-
blasts. Myogenin-null mice, in accordance with the appear-
ance of myogenin at the onset of differentiation, die perina-
tally due to a severe deficiency of differentiated muscle fibers
(Hasty et al., 1993; Nabeshima et al., 1993). As would be
expected, upregulation of these transcription factors by
ATP: (a) potentiated terminal differentiation of satellite
cells, as judged by the expression of MHC and myotube for-
mation; and (b) inhibited satellite cell proliferation. Consis-
tent with evidence that ATP increased expression of p21, we
found that the effect of ATP was irreversible. Incubating
cells with media containing 100  M ATP for 1 min, fol-
lowed by replacement with fresh medium still produced a
reduction in cell number.
The antiproliferative effects of ATP at 24 h could not be
replicated by application of adenosine, ADP, UTP, or
 - -methylene ATP, and were inhibited by PPADS, but
not RB2. However, PPADS is effective at P2Y1 receptors
(Schachter et al., 1996, 1997); as ADP (a P2Y1 receptor ag-
onist) had no effect on cell number, this receptor is unlikely
to be involved. Therefore, antagonism by PPADS would
implicate a P2X receptor (P2X1, P2X2, P2X3, or P2X5)
(Lambrecht, 2000). The fact that the P2X1- and P2X3-
selective agonist,  - -methylene ATP, was found to have
no significant effect on cell number, suggests that the recep-
tor involved contained the P2X2 or P2X5 receptor subunits.
However, RB2 an antagonist at the P2X2, but not the P2X5,
receptor subunit (King et al., 1997; Wildman, S.S., S.G.
Brown, M. Rahman, G. Burnstock, J. Urwin, and B.F.
King. 2002. Joint Meeting: The Physiological Society,
Scandinavian Physiological Society, and Deutsche Physiol-
ogische Geselschaft. 81st Annual Meeting. 31 [Abstr.]),
could not inhibit the effects of ATP on cell number. There-
fore, although we cannot rule out the possibility of a novel,
yet to be cloned receptor, this data points strongly to the in-
volvement of the P2X5 receptor.
P2Y receptors are also known to be present in skeletal
muscle (Parr et al., 1994; Meyer et al., 1999a; Choi et al.,
2001) and the increase in cell number on UTP application
could be explained by activation of a P2Y2 or P2Y4 receptor.
Because prolonged application of adenosine produced a sig-
nificant reduction in cell number, which could be inhibited
by preapplication of the P1 antagonist, 8-SPT, the presence
of a P1 receptor was also demonstrated. However, the effect
of ATP applied for 1 min, could only be inhibited by preap-
plication of PPADS and not 8-SPT. These results suggest
that although P1 and P2Y receptors are expressed by satellite
cells, a P2X receptor is primarily responsible for the effects
of ATP studied in this paper.
The antiproliferative and differentiating effects of ATP
could be considered counterintuitive. An obvious, but by no
means the only, source of ATP under physiological condi-352 The Journal of Cell Biology | Volume 158, Number 2, 2002
tions is damaged myofibers. However, muscle trauma, far
from inhibiting satellite cell proliferation, activates quiescent
satellite cells to reenter the cell cycle and proliferate. Trauma
also results in the release of many other trophic factors, in-
cluding hepatocyte growth factor and FGFs, known to be
capable of promoting satellite cell proliferation (Hawke and
Garry, 2001). Therefore, purinoceptor signaling is likely to
be only one of many active systems in vivo. Maintenance of
cells in high-serum media (GM), when increased levels of
trophic factors are likely to be present, could be considered
analogous to these conditions. We found that ATP had no
effect on cell number even at a concentration of 100  M,
when cells were maintained in GM. Furthermore, under
low-serum conditions, ATP not only inhibited cell prolifera-
tion, but also potentiated differentiation. This would sug-
gest that the ATP effects studied in this paper relate predom-
inantly to late events in muscle regeneration, when the levels
of other trophic factors have fallen and controlled release of
ATP from motoneurons (Redman and Silinsky, 1994; Silin-
sky and Redman, 1996) and muscle activity (Smith, 1991;
Cunha and Sebastiao, 1993; Hellsten et al., 1998) can influ-
ence satellite cell activity.
One way of varying the response of satellite cells to ATP is
to regulate receptor expression. We found that whereas cells
maintained in GM expressed no P2X receptor proteins, cells
maintained in DM expressed high levels of the P2X5 recep-
tor subunit. Furthermore, maintaining cells in low-serum
medium increased the expression of P2X5 receptor mRNA
and stimulated the expression of P2X2 receptor mRNA. Be-
cause the only P2X receptor to be differentially expressed
(on the basis of protein and mRNA) was P2X5, this would
implicate this receptor in the differential response of cells
maintained in growth or differentiation medium to ATP
and consequently the antiproliferative effects of ATP. Cer-
tainly the pharmacological profile observed (see above) is
consistent with this suggestion.
The mechanism by which P2X5 receptor activation pro-
duced effects on satellite cell activity was also investigated.
We were able to demonstrate that ATP application to satel-
lite cells produced a significant and rapid increase in the
phosphorylation of p38 and, to a lesser extent, ERK 1/2.
However, only inhibition of p38  and p38  activation
blocked the P2X-dependent effects on cell number. These re-
sults are consistent with previous studies demonstrating the
importance of the p38 MAPK signaling pathway in myogen-
esis. p38 can directly activate the MEF2 transcription factors
in skeletal muscle (Zetser et al., 1999; Wu et al., 2000), and
together with the MyoD family, MEF2 transcription factors
are necessary for the differentiation of myoblasts (Black and
Olson, 1998; Molkentin et al., 1995). Thus, overexpression
of p38 isoforms or upstream activators stimulate myogenesis,
whereas inhibition of p38 activation prevents formation of
myotubes (Wu et al., 2000; Zetser et al., 1999).
P2X5 receptor activation results in a rapid and transient
flow of cations across the plasma membrane. Thus, like all
ionotropic receptors, P2X5 has been viewed as a mediator of
transient cellular events. However, recent research on vari-
ous ligand-gated ion channels, including P2X7 (a member of
the P2X receptor family), demonstrates that ionotropic re-
ceptors interact with cytoskeletal and signaling proteins
(Sheng and Pak, 2000; Kim et al., 2001) and can produce
long-term effects on cellular activity. A number of proteins
capable of activating intracellular signalling pathways have
been shown to interact with the P2X7 receptor, such as
phosphatidylinositol 4-kinase (Kim et al., 2001), and it is
known that this receptor can activate the p38, ERK 1/2 and
JNK MAPK signaling cascades (Humphreys et al., 2000;
Panenka et al., 2001). Furthermore, activation of the P2X7
receptor has been shown to produce caspase-dependent ap-
optosis in various cell types, including microglia, dendritic,
and mesangial cells (Schulze-Lohoff et al., 1998; Coutinho
Silva et al., 1999; Ferrari et al., 1999). Thus, the results pre-
sented in this paper suggest that activation of the P2X5 re-
ceptor can produce changes in MAPK signaling pathways by
analogous mechanisms.
Although in this paper we have only investigated satellite
cells in vitro, recent immunohistochemical and in situ lo-
calization studies demonstrate that P2X receptors, notably
P2X5, are also expressed during skeletal muscle formation in
vivo (Meyer et al, 1999b; Ruppelt et al., 2001; Ryten et al.,
2001). P2X2, P2X5, and P2X6 receptor expression have
been demonstrated in developing rat and chick skeletal
muscle (Meyer et al, 1999b; Ruppelt et al., 2001; Ryten et
al., 2001). In chick, P2X5 receptor mRNA and protein was
detected not only on myotubes, but also muscle precursor
cells in the dermamyotome (Meyer et al., 1999b; Ruppelt et
al., 2001). These results suggest that signaling through a
P2X receptor containing the P2X5 subunit may be impor-
tant in muscle formation in vivo, whether in development
or regeneration of skeletal muscle. Similarly, immunohis-
tochemical localization of P2X5 in the differentiating cell
layers of stratified squamous epithelial tissues suggest a gen-
eral function for P2X5 receptor-mediated signaling in regu-
lating the balance between cell proliferation and differentia-
tion in a variety of systems.
In summary, we demonstrate in this paper a novel role for
ATP in the regulation of skeletal muscle formation. Under
differentiating conditions, ATP acts on satellite cells to in-
hibit proliferation and increase the rate of differentiation.
These effects are mediated by upregulation of myogenin and
the cell cycle regulator p21. Surprisingly, the effect of ATP is
due to the activation of an ionotropic P2X receptor, con-
taining the P2X5 receptor subunit. Although a role for P2X5
in cell differentiation has been proposed, this is the first
functional evidence. Thus these results not only open the
way for a new therapeutic target in the treatment of myo-
genic disorders, but also a new role for P2X receptors in the
control of cell cycle and fate.
Materials and methods
Tissue culture
Primary cultures of skeletal muscle satellite cells were prepared using a
protocol adapted from Daniels et al. (2000). Briefly, skeletal muscle was
dissected from the hindlimbs of 1- to 2-d-old, neonatal Sprague Dawley
rats and finely chopped using a McIlwain Tissue Chopper. After digestion
in trypsin and collagenase (Sigma-Aldrich), the resulting suspension was
filtered using a 200  m mesh and centrifuged. The pellet was resus-
pended and the resulting cell suspension preplated to remove fibroblasts.
Cells were then replated on 1% gelatin-coated dishes and maintained for
1 to 2 days in DME supplemented with 10% FCS, 10% normal horse se-
rum (NHS; GIBCO-BRL), 0.5% gentamicin, and 0.5% ampicillin (termed
GM; Sigma-Aldrich). Skeletal satellite cells were then selectively detached ATP regulates skeletal muscle differentiation | Ryten et al. 353
using 0.05% Dispase II (Roche), preplated to remove fibroblasts, and then
finally plated at 10
4 cells/cm
2 on laminin-coated coverslips or plasticware
as appropriate. Cells were maintained in GM or DME supplemented with
5% NHS (DM), at 37 C and 5% CO2. Freshly isolated cells were used for
each experiment.
Electrophysiology
Whole-cell patch clamp recordings were carried out as described previ-
ously by Zhong et al. (1998). Agonists were applied rapidly by microperfu-
sion from a four-barrel manifold controlled by computer-driven solenoid
valves. Data were acquired using pClamp v8 software (Axon Instruments),
and plotted using Origin v4.1 (Microcal). The current–voltage relationship
for the ATP activated current was obtained by subtracting the current re-
sponse to a ramped change in voltage ( 60 to  20 mV, 0.6 s) in the ab-
sence of agonist from that recorded in the presence of ATP.
Immunocytochemistry
Skeletal satellite cells were plated on laminin-coated glass coverslips or
laminin-coated 8-well LabTek chamberslides (Nunc Life Technologies) for
immunocytochemistry. In both cases, cells were fixed for 20 min in 4%
paraformaldehyde. After washing in PBS, cells were permeabilized and non-
specific binding sites were blocked using 10% normal goat serum (NGS)  
0.2% Triton X-100 in PBS. Fixed cells were incubated with primary anti-
bodies, diluted in 10% NGS   0.2% Triton X-100 in PBS, overnight at room
temperature. The primary antibodies used were rabbit anti-P2X1–7 (Roche);
rabbit anti-P2Y1, P2Y2, and P2Y4 (Alomone Laboratories); MF20 (University
of Iowa Developmental Studies Hybridoma Bank); and rabbit antiskeletal
myosin (Sigma-Aldrich). These antibodies were used at the following con-
centrations: rabbit anti-P2X1–7, 5  g/ml; MF20, 1:100 of hybridoma super-
natant; and rabbit antiskeletal myosin, 1:100. After washing in PBS, cells
were incubated with fluorescence-labeled secondary antibodies for 1 h at
37 C. Donkey anti–rabbit Cy3 (1:500 in 1% NHS in PBS) or Oregon green–
labelled goat anti–mouse/rabbit secondary antibodies (Stratech Scientific)
(1:100 in 1% NGS in PBS) were applied as appropriate. In some cases, cell
nuclei were also stained by incubation with DAPI (Sigma-Aldrich) at 0.6  g/
ml in PBS for 1 h at room temperature. Control experiments were carried out
with the primary antibody omitted from the staining procedure and, in the
case of the rabbit anti-P2X1–7 antibodies, the primary antibody preabsorbed
with the peptides used to immunize the rabbits.
Drugs used
ATP, ADP, UTP,  - -meATP (lithium salt), RB2, 8-SPT, and 3,3 -methylene-
bis-(4-hydroxy-coumarin) (dicumarol) were purchased from Sigma-Aldrich.
PPADS (tetrasodium salt) was supplied by Tocris Cookson Ltd. The kinase in-
hibitors PD98059, U0126, and SB203580 were purchased from Calbiochem.
Cell counting
Cell number was assessed directly, after trypsin treatment, by staining with
trypan blue for viability and counting using a haemocytometer, or indi-
rectly by DNA quantification using the Fluoreporter Blue Fluorometric ds-
DNA Quantification kit (Molecular Probes).
MHC expression
The number of cells positive for MHC was assessed by first staining cultures
with MF20 (see above) and then counting the number of immunoreactive
cells in five random fields on three separate coverslips for each treatment.
Myotube assay
Skeletal satellite cells were plated at a density of 5   10
4 cells/cm
2 on
laminin-coated glass coverslips and maintained in GM overnight. After
treatment for 24 h, cells were fixed in 4% paraformaldehyde for 20 min.
Myotubes were scored for five random fields on three separate coverslips
for each treatment.
Data analysis
Cell/myotube number was expressed as a percentage of that at time zero or
as a percentage of the cell/ myotube number in the untreated, control wells
after the same time in culture. Each experiment was conducted at least three
times with separate preparations of satellite cells. Test and control cultures
were run in parallel on each occasion. Differences in cell/myotube number
were assessed for significance using a paired, two-tailed Student’s t test.
BrdU incorporation assay
Skeletal satellite cells were plated at a density of 1   10
4 cells/cm
2 on lami-
nin-coated glass coverslips and maintained in DM overnight. Cells were
then treated with ATP and maintained for 12 h, prior to addition of BrdU (at
a concentration of 50  M). After a further 12 h, coverslips were washed
with PBS to remove nonadherent cells and the remaining cells fixed with
95% ethanol. Cells were treated with 2 M hydrochloric acid, washed with
PBS and incubated with 10% NGS   0.2% Triton X-100 in PBS for 1 h. The
cells were then incubated with mouse anti-Brdu antibody, 1:1,000 in 10%
NGS in PBS (Sigma-Aldrich) overnight and staining visualized using Ore-
gon green-labelled goat anti–mouse secondary antibody (Stratech Scien-
tific). Nuclei were stained using DAPI. The percentage of proliferating cells
(nuclei immunopostive for BrdU/nuclei staining for DAPI) was scored for
five random fields on three separate coverslips for each treatment.
RT-PCR
Total RNA was extracted from skeletal satellite cells using the SV Total RNA
Isolation System (Promega). RT-PCR was performed using Ready-to-Go RT-
PCR beads (Amersham Pharmacia Biotech). Reverse transcription was per-
formed using the Moloney murine leukemia virus reverse transcriptase.
Primer sequences for P2X1–7 (Shibuya et al., 1999), p21 (Wong et al., 2000),
and myogenin and 16S (Ogilvie et al., 2000) were used for amplification re-
actions, as reported previously. The amplification reaction, performed in the
same reaction tube, was conducted under the following conditions 95 C for
30 s, the relevant annealing temperature for 30 s, and 72 C for 1 min, plus
an additional cycle with an elongation time of 5 min. To normalize mRNA
levels between samples, PCR reactions were performed for 16 s (ribosomal
protein). Amplification products were separated by electrophoresis and vi-
sualized by ethidium bromide staining. According to densitometric analysis
of the PCR products (BioRad Multi-Imager software), sample loading was
adjusted for subsequent PCR reactions for P2X1–7, p21, and myogenin. The
presence of possible contaminants was investigated in all experiments, us-
ing control RT-PCR reactions in which, either mRNA had been omitted or
the reverse transcriptase had been inactivated by heating to 95 C.
Protein preparation and Western blotting for the MAPK proteins
Skeletal satellite cells were plated at a density of 1   10
4 cells/cm
2 on
laminin-coated dishes and maintained in DM overnight. Cells were then
treated with 100  M ATP for time periods ranging from 0 min to 24 h. Af-
ter treatment with ATP, cells were quickly rinsed twice with ice-cold PBS,
collected in PBS, and pelleted at 13,000 g for 10 min. Cells were then
lysed in a buffer containing 20 mM Tris, pH 7.0, 0.27 M sucrose, 1 mM
EDTA, 1 mM EGTA, 50 mM sodium fluoride, 1 mM DTT, 1 mM sodium
orthovanadate, 10 mM sodium  -glycerophosphate, 1% Triton X-100, 1
 g/ml pepstatin A, 4  M leupeptin, 30  l/ml aprotinin, and 0.1 mg/ml
AEBSF (Calbiochem) for 20 min on ice. The resulting homogenate was
centrifuged at 13,000 g for 10 min. The protein concentration was deter-
mined using the modified Lowry procedure (Peterson, 1983).
Samples containing equal amounts of protein were subjected to SDS-
PAGE using 11% acrylamide and transferred to nitrocellulose filters. Filters
were incubated with a blocking solution containing 20 mM Tris, pH 7.7,
137 mM NaCl, 0.1% Tween 20 (TTBS), and 5% nonfat dry milk for 1 h at
room temperature, rinsed in TTBS, and then incubated for 1 h at room tem-
perature with specific primary antibodies. The antibodies used were all di-
luted in 5% bovine serum albumin in TTBS at the following concentrations:
rabbit ant-ERK 1/2, 1:5,000 (Cell Signaling Technology); rabbit anti-phos-
pho-ERK 1/2, 1:2,000 (Santa Cruz Biotechnology); rabbit anti-p38, 1:1,000
(Cell Signaling Technology); and mouse anti–phospho-p38, 1:1,000 (Cell
Signaling Technology). After three rinses in TTBS, filters were incubated for 1 h
at room temperature with peroxidase-conjugated anti–rabbit or anti–mouse
IgG diluted in TTBS (1:20,000 or 1:10,000, respectively) (Amersham Life
Sciences). Filters were washed three times in TTBS, and proteins were de-
tected by enhanced chemiluminescence (Amersham Life Sciences). Results
were analysed using densitometry (Bio-Rad Multi-Imager software).
The MF20 monoclonal antibody developed by Donald A. Fischman was
obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA).
The authors thank Yuan Kang for her help and technical assistance, and
Roche Bioscience for providing antibodies.
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